These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 21957829

  • 1. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
    Webster LR, Messina J, Xie F, Nalamachu S.
    J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
    [Abstract] [Full Text] [Related]

  • 2. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM, Messina J, Xie F, Hale M.
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [Abstract] [Full Text] [Related]

  • 3. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK, Messina J, Xie F, Peppin J.
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [Abstract] [Full Text] [Related]

  • 4. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
    Slatkin NE, Xie F, Messina J, Segal TJ.
    J Support Oncol; 2007 Jan; 5(7):327-34. PubMed ID: 17708123
    [Abstract] [Full Text] [Related]

  • 5. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
    Portenoy RK, Taylor D, Messina J, Tremmel L.
    Clin J Pain; 2006 Jan; 22(9):805-11. PubMed ID: 17057563
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
    Überall MA, Müller-Schwefe GH.
    Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study.
    Fine PG, Messina J, Xie F, Rathmell J.
    J Pain Symptom Manage; 2010 Nov; 40(5):747-60. PubMed ID: 20594801
    [Abstract] [Full Text] [Related]

  • 13. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients.
    Nalamachu SR, Narayana A, Janka L.
    Curr Med Res Opin; 2011 Apr; 27(4):751-60. PubMed ID: 21288055
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
    Fine PG, Narayana A, Passik SD.
    Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T.
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
    Taylor DR, Webster LR, Chun SY, Reinking J, Stegman M, Shoemaker S, Fortner B.
    Pain Med; 2007 Apr; 8(3):281-8. PubMed ID: 17371416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.